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Abstract
Urate is a major antioxidant as well as the enzymatic end product of purine metabolism in humans. Higher levels correlate
with a reduced risk of developing Parkinson’s disease (PD) and with a slower rate of PD progression. In this study we
investigated the effects of modulating intracellular urate concentration on 1-methyl-4-phenyl-pyridinium (MPP
+)-induced
degeneration of dopaminergic neurons in cultures of mouse ventral mesencephalon prepared to contain low (neuron-
enriched cultures) or high (neuron-glial cultures) percentage of astrocytes. Urate, added to the cultures 24 hours before and
during treatment with MPP
+, attenuated the loss of dopaminergic neurons in neuron-enriched cultures and fully prevented
their loss and atrophy in neuron-astrocyte cultures. Exogenous urate was found to increase intracellular urate content in
cortical neuronal cultures. To assess the effect of reducing cellular urate content on MPP
+-induced toxicity, mesencephalic
neurons were prepared from mice over-expressing urate oxidase (UOx). Transgenic UOx expression decreased endogenous
urate content both in neurons and astrocytes. Dopaminergic neurons expressing UOx were more susceptible to MPP
+ in
mesencephalic neuron-enriched cultures and to a greater extent in mesencephalic neuron-astrocyte cultures. Our findings
correlate intracellular urate content in dopaminergic neurons with their toxin resistance in a cellular model of PD and
suggest a facilitative role for astrocytes in the neuroprotective effect of urate.
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Introduction
Urate (2,6,8-trioxy-purine; a.k.a. uric acid) is generated within
cells from the breakdown of purines. In most mammals urate is
converted to allantoin by uricase (urate oxidase; UOx) [1], an
enzyme primarily expressed in the liver [2]. In humans and apes,
uricase is not synthesized due to the sequential non-sense
mutations of its gene (UOx) that occurred during hominoid
evolution [3–5]. Thus, in humans urate is the end product of the
purine catabolism and achieves concentrations approaching the
limit of solubility, which are more than fifty times higher than
those in other mammals [6]. Due its high levels and radical
scavenging properties [7–9] urate is considered a major antiox-
idant circulating in humans. It may have played a facilitative role
in human evolution as was initially proposed based on putative
central nervous system benefits [10–12] and later based on its
antioxidant properties – perhaps to have partially compensated for
the lost of the capability of synthesizing ascorbate [7,13]. Urate’s
antioxidant proprieties have been extensively characterized in vitro
where it was found to be a peroxynitrite scavenger [14] and to
form stable complex with iron ions, reducing their oxidant
potential [15].
Identification of these antioxidant proprieties of urate, together
with evidence that oxidative damage plays a critical role in the
neurodegeneration of PD, raises the possibility that urate may
protect from the development of the disease. Prompted further by
post-mortem evidence that the urate levels in midbrain and
striatum of PD patients are reduced compared to those of control
brains [16], epidemiological and clinical cohorts were investigated
for a possible link between urate level and the risk of PD or the
rate of its progression. Several studies found lower blood urate
concentration in healthy individuals to be a reproducible risk
factor for developing PD later in life [17–19]. Furthermore, among
those already diagnosed with PD, lower serum levels were
consistently associated with a more rapid clinical and radiographic
progression of PD [20–22], suggesting urate may be a prognostic
biomarker in PD. In addition, an inverse correlation between
serum urate level and disease duration has been reported in PD
and raises the possibility that urate may also be a marker of disease
stage [23], though falling urate may simply reflect the weight loss
that accompanies disease duration.
A causal basis for the link between urate and favorable
outcomes in PD is supported by the neuroprotective properties
of urate in models of PD. Presumably by reducing ROS levels,
urate can prevent cellular damage and increase cell viability in in
vitro models of toxicant-induced or spontaneous cell death [24–27].
Moreover, urate increased cell survival in MPP
+-treated cell
cultures [28] and prevented dopaminergic neuron loss in a rodent
model of PD [29].
MPP
+ (1-methyl-4-phenylpyridinium) is the toxic metabolite of
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) [30], an
agent shown to induce a parkinsonian condition in humans [31].
MPP
+ is generated in astrocytes and up-taken by dopamine
transporter into dopaminergic neurons [32]. Within the cells,
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+ can induce the irreversible inhibition of complex I activity,
failure of ATP synthesis and cell death [33,34]. In this study we
assessed whether modulating urate level in primary dopaminergic
neurons affects their vulnerability to MPP
+ toxicity in the presence
of a low or high percentage of astrocytes.
Results
Urate prevents dopaminergic neuron loss in MPP
+-
treated cultures
To identify an MPP
+ concentration with selective toxicity for
dopaminergic neurons, mesencephalic neuron-enriched cultures
(Fig. 1A–D) were treated for 24 hours with increasing concentra-
tions of MPP
+. Toxicant treatment reduced the number of
dopaminergic neurons, which were identified by their immuno-
reactivity for tyrosine hydroxylase (TH), in a concentration-
dependent manner (P,0.0001). There was no change in the total
number of neurons, which were scored as microtubule-associated
protein 2-immunoreactive (MAP-2-IR) cells (Fig. 2A), due to the
selectively toxic effect of MPP
+ on dopaminergic neurons and their
low number in ventral mesencephalon cultures (2–3% of MAP-2-
IR cells; see also Materials and Methods). To assess the effect of
urate on dopaminergic neuron viability, neuron-enriched cultures
were pretreated with urate 24 hours before and during exposure to
3 mM MPP
+. In MPP
+-treated cultures urate increased TH-IR
viability over a concentration range of 0.1–100 mM( P,0.0001).
The maximum effect was achieved at 100 mM with a 51% increase
in TH-IR cell number in comparison to cells treated with MPP
+
only (P,0.01). Half-maximally effective concentration (EC50) was
achieved at a concentration of 1 mM [95% confidence interval
(95%CI): 0.096–5.9] (Fig. 2B, D–G). Urate on its own produced no
significant effect on dopaminergic neuron viability (Fig. 2C).
Previous data [35] have shown that urate’s protective effect
against toxin-induced neuronal cell death can be dependent on the
presence of astrocytes in cultures. In our study urate treatment in
neuron-enriched cultures only partially attenuated MPP
+ toxicity
on dopaminergic neurons. To assess whether astrocytes might
potentiate the protective effect of urate in our cells, urate was
tested in MPP
+-treated mixed neuron-astrocyte cultures (Fig. 3A–
D). To obtain selective degeneration of dopaminergic neurons
without toxic effect on non-TH-IR cells, cultures were treated with
relatively low concentrations of MPP
+ for four days as previously
described [36]. MPP
+ induced selective loss of TH-IR neurons in a
concentration-dependent manner (P=0.0005) with no statistically
significant effect on MAP-2-IR or glial fibrillary acid protein-
immunoreactive (GFAP-IR) cells (Fig. 4A). To assess the effect of
urate, neuron-astrocyte cultures were pretreated with urate
24 hours before and during exposure to 0.5 mM MPP
+. Urate
increased the number of TH-IR neurons over a concentration
range of 0.1–100 mM( P,0.0001). The maximum effect was seen
at 100 mM with a 97% increase in the number of TH-IR neurons
in comparison to cultures treated with MPP
+ only (P,0.01;
Fig. 4B, F–I), corresponding to a complete blockade of MPP
+
toxicity. Urate on its own did not affect TH-IR cell number
(Fig. 4C). No statistically significant difference was seen at the
estimated EC50’s for urate in neuron-enriched and neuron-
astrocytes cultures (,1 mM in both; F1,53=0.01, P=0.9).
Urate prevents MPP
+-induced atrophic changes in
dopaminergic neurons
To assess whether the protective effect of urate on neuronal
viability correlates with an improvement in toxin-induced cellular
atrophy, neurite length and soma size were analyzed in neuron-
astrocyte cultures. In MPP
+-treated cultures TH-IR cells showed
shorter neurites (232%, P,0.01) and smaller soma area (220%,
P,0.001) in comparison to control cells (Fig. 4D and E,
respectively). The concentration that fully protected against
dopaminergic neuron loss, 100 mM urate, prevented the decrease
in neurite length (P,0.01) and soma size (P,0.001) in TH-IR
neurons (Fig. 4D–E).
Exogenous urate raises its intracellular level
To assess whether urate’s protective effects are associated with
an increase in its intracellular content, neuron-enriched cultures
were treated with exogenous urate for 0, 6 and 24 hours. In order to
obtain the large number of neurons required for intracellular
analyte measurements, cultures were prepared from the mouse
cortex for this assay. Urate content in neurons increased in a time-
dependent manner with about 4 fold increase at 24 hours of
treatment (P=0.002) (Fig. 5A), the time at which MPP
+ would be
added to the cultures. Exogenous urate did not affect the
concentration of any measured urate precursor (adenosine,
inosine, hypoxanthine and xanthine) within neurons (unpublished
data). Similar results were obtained in astrocyte-enriched cultures
(unpublished data).
Transgenic UOx expression lowers intracellular urate
To assess whether intracellular urate content affects dopami-
nergic neuron resistance to MPP
+ we prepared ventral mesen-
cephalon cultures from a mouse line expressing transgenic uricase
(UOx) [37], the enzyme that converts urate to allantoin.
Intracellular urate content was measured in cortical neurons and
astrocytes prepared from non-transgenic UOx (non-Tg), hemizy-
gous transgenic UOx (Tg) and homozygous (double) transgenic
UOx (Tg/Tg) mice. In Tg/Tg neurons UOx expression was about
6 times higher than in Tg neurons as assessed by western blotting;
in non-Tg neurons UOx was not detected (Fig. 6A). UOx
expression reduced intracellular urate content by 50% (P,0.01)
and 60% (P,0.01) in Tg and Tg/Tg neurons, respectively
Figure 1. Cellular composition of neuron-enriched cultures.
Composite fluorescence photomicrographs of neuron-enriched cultures
that were immuno-stained with A–D) the neuronal marker MAP-2
(green) together with A) astrocyte marker GFAP (red) or B) the microglia
marker CD11b (red, not detected) or C) the oligondendrocyte marker
CNPase (red, not detected) or D) the dopaminergic neuron marker TH
(yellow). Nuclei were counterstained with DAPI; scale bar length
represents 100 mm.
doi:10.1371/journal.pone.0037331.g001
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(p,0.001) but not in Tg cell medium in comparison to non-Tg
samples (Fig. 6C). In Tg/Tg astrocytes intracellular UOx
expression was about 15 times higher than in Tg astrocytes; in
non-Tg astrocytes UOx was not detected (Fig. 7A). UOx
expression reduced intracellular urate content by 30% both in
Tg and Tg/Tg (P,0.01) astrocytes (Fig. 7B). UOx activity was
detected in the cell media of Tg and Tg/Tg astrocytes (Fig. 7C)
where medium urate concentration was significantly reduced in
comparison to that from non-Tg astrocytes (P,0.001) (Fig. 7D).
Transgenic UOx reduces neuronal resistance to MPP
+
toxicity
To determine whether the enzymatic reduction of intracellular
urate exacerbates dopaminergic susceptibility to MPP
+, neuron-
enriched ventral mesencephalon cultures from non-Tg, Tg and
Tg/Tg mice were treated with increasing concentrations of toxin
for 24 hours. Two-way ANOVA showed that both genotype
(F2,232=24.61, P,0.0001) and MPP
+ concentration
(F2,232=312.64, P,0.0001) affected the number of TH-IR
neurons, and found significant interaction between these two
factors (F2,232=13.82, P,0.0001). Dopaminergic viability was
reduced in UOx expressing cultures in comparison to non-Tg
cultures with a maximum effect at 1 mM MPP
+, which further
reduced TH-IR neuron number by 10% and 18% in Tg and Tg/
Tg cultures compared to non-Tg cultures, respectively (Fig. 8A).
Figure 2. Urate’s protective effect on dopaminergic neurons in neuron-enriched cultures. A) MPP
+ concentration-dependent effect on
dopaminergic and total neuron viability expressed respectively as percentage of TH- and MAP-2-IR cell number in comparison to control cultures
(n=5). B) Urate concentration-dependent effect on TH-IR cell number in 3 mM MPP
+-treated cultures (n=7). C) Lack of urate effect at any
concentration on TH-IR neuron number in control (MPP
+-untreated) cultures (n=5). Photomicrographs show TH-IR neurons in D) control cultures, E)
MPP
+/0 urate-treated cultures, F) MPP
+/0.1 urate-treated cultures and G) MPP
+/100 mM urate-treated cultures. Scale bar=50 mm. One-way ANOVA
followed by Newman-Keuls test: **P,0.01, ***P,0.001 vs 0 MPP
+ value;
#P,0.05,
##P,0.01 vs MPP
+/0 urate value.
doi:10.1371/journal.pone.0037331.g002
Figure 3. Cellular composition of neuron-astrocyte cultures.
Composite fluorescence photomicrographs of neuron-astrocyte cul-
tures that were immuno-stained with A–C) the neuronal marker MAP-2
(green) together with A) astrocyte marker GFAP (red) or B) the microglia
marker CD11b (red) or C) the oligondendrocyte marker CNPase (red, not
detected). D) Dopaminergic neurons were stained with the dopami-
nergic neuron marker TH (red). Nuclei were counterstained with DAPI;
scale bar is 100 mm.
doi:10.1371/journal.pone.0037331.g003
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+ was 5.2 mM (95%CI: 2.8–9.7 mM) in non-Tg
cultures, 3.9 mM (95%CI: 2.4–6.4 mM) in Tg and 2.5 mM
(95%CI: 0.9–6.8 mM) in Tg/Tg without statistically significant
difference among genotypes (F2,232=0.5612, P=0.57).
Two-way ANOVA of MPP
+-toxicity on MAP-2-IR cell number
revealed significant effect of MPP
+ concentration (F2,199=28.47,
P,0.0001), but neither a significant effect of genotype
(F2,199=1.64, P=0.20) nor a significant interaction between these
two factors (F2,199=1.20, P=0.31) (Fig. 8B).
To assess whether reducing basal urate levels in both, neurons
and astrocytes, exacerbated the UOx effect on MPP
+-induced
toxicity, we treated neuron-astrocyte cultures with MPP
+ for four
days as mentioned above. Two-way ANOVA revealed significant
effects of both genotype (F2,284=10.09, P,0.0001) and MPP
+
concentration (F2,284=96.36, P,0.0001) on the number of TH-IR
neurons and a significant interaction between genotype and MPP
+
concentration (F2,284=3.01, P=0.007) (Fig. 9A). Dopaminergic
viability was reduced in UOx expressing cultures in comparison to
non-Tg cultures with a maximum effect at 0.1 mM MPP
+, which
further reduced TH-IR neuron number by 39% and 49% in Tg
and Tg/Tg cultures compared to non-Tg cultures, respectively.
The EC50 for MPP
+ was 0.11 mM (95%CI: 0.04–0.31 mM) in non-
Figure 4. Urate’s protective effect on dopaminergic neurons in mixed cultures. A) MPP
+ concentration-dependent effect on dopaminergic
neuron, total neuron and astrocyte viability, expressed as percentage of TH-IR, MAP-2-IR and GFAP-IR cell number, respectively, in comparison to
control cultures (n=4). B) Urate concentration-dependent effect on TH-IR cell number in 0.5 mM MPP
+-treated cultures (n=5). C) Lack of effect of
urate at any concentration on TH-IR cell number (n=5). Urate (100 mM) effects on reductions in D) longest neurite length and E) soma size in MPP
+
urate-treated TH-IR neurons. Photomicrographs show TH-IR neurons in F) control cultures, G) MPP
+/0 urate-treated cultures and H) MPP
+/0.1 urate-
treated cultures and I) MPP
+/100 mM urate-treated cultures. Scale bar=50 mm. One-way ANOVA followed by Newman-Keuls test: *P,0.05, **p,0.01,
***P,0.001 vs 0 MPP
+ value,
##P,0.01 and
###P,0.001 vs MPP
+/0 urate value.
doi:10.1371/journal.pone.0037331.g004
Figure 5. Urate accumulation in cortical neurons. A) Time-
dependent effect of 100 mM exogenous urate on its intracellular content
in primary cortical neurons. One-way ANOVA followed by Newman-
Keuls test: **P,0.01.
doi:10.1371/journal.pone.0037331.g005
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(95%CI: 0.01–0.04 mM) in Tg/Tg with a statistically significant
difference among genotypes (F2,284=5.66, P=0.0039).
Analysis of MPP
+ effect on MAP-2-IR cell number revealed
significant effect of MPP
+ concentration (F2,236=5.89, P,0.0007),
but neither a genotype effect (F2,236=0.27, P=0.76) nor
significant interaction between these two factors (F2,236=0.06,
P=1) (Fig. 9B).
These data indicate that dopaminergic tolerance to MPP
+ was
further reduced when basal urate content was reduced both in
neurons and astrocytes.
Discussion
In our model we induced selective degeneration of dopaminer-
gic neurons using the neurotoxin MPP
+ in mouse ventral
mesencephalon cultures. Urate, a known powerful antioxidant
[7–9], added to cultures 24 hours before and during toxicant
treatment, attenuated MPP
+ toxicity in dopaminergic neurons. It
increased the number of TH-IR cells both in neuron-enriched and
neuron-astrocyte cultures containing respectively low and high
percentage of astrocytes. In cultures with low percentage of
astrocytes, urate only partially prevented dopaminergic neuron
loss. On the other hand, in cultures prepared with a high
percentage of astrocytes, urate completely prevented MPP
+-
induced toxicity. Moreover, in these mixed neuron-astrocyte
cultures, urate fully prevented atrophic morphological changes in
neurite length and soma size induced by MPP
+. Both in neuron-
enriched and neuron-astrocyte cultures, urate showed protective
effects with an EC50 of about 1 mM, a concentration within the
mouse physiological range where its CSF urate concentration is
about 3 mM [38], ten-time lower than in humans [6].
Urate may have conferred protection against neuronal atrophy
and death through its established antioxidant actions, as it has
been shown to prevent ROS accumulation and oxidative damage
in other neuronal populations [25,26,39] and to raise cysteine
uptake and glutathione synthesis in mouse hippocampal slices
[40]. Urate treatment might change the redox status of neurons,
reducing their vulnerability to oxidative stress and preventing
cellular degeneration. In fact, MPP
+ toxicity may depend on the
Figure 6. Characterization of non-Tg, Tg and Tg/Tg cortical neuron-enriched cultures. A) Western blot and graph showing UOx expression
in wild-type (non-Tg) and UOx-expressing neurons (Tg and Tg/Tg) normalized to the b-actin level. Note that UOx was not detected in wild-type
neurons (n=3). B) Effect of UOx expression on intracellular urate content in neurons normalized to the protein level (n=3). C) UOx activity in the
media of non-Tg and UOx-expressing neurons (n=6). Student’s t test:
##P=0.005 vs Tg value; one-way ANOVA followed by Newman-Keuls test:
**P,0.01, ***P,0.001 vs non-Tg value and
###P,0.001 vs Tg value.
doi:10.1371/journal.pone.0037331.g006
Figure 7. Characterization of non-Tg, Tg and Tg/Tg cortical
astrocyte-enriched cultures. A) Western blot and graph showing
UOx immunostaining in non-Tg and UOx-expressing astrocytes (Tg and
Tg/Tg) normalized to the b-actin level. Note that UOx was not detected
in non-Tg astrocytes (n=7). B) Effect of UOx expression on the
intracellular urate content normalized to the protein level (n=5). C) UOx
activity in the media of non-Tg and UOx-expressing astrocytes (n=9). D)
Effect of UOx expression on extracellular urate concentration in
astroglial cultures (n=6). Some error bars are not visible because of
their small size. Student’s t test:
###P,0.0001 vs Tg value. One-way
ANOVA followed by Newman-Keuls test: *P,0.05, ***P,0.001 vs non-
Tg value.
doi:10.1371/journal.pone.0037331.g007
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toxic levels of iron and glutathione synthesis inhibition to enhance
degeneration of dopaminergic neurons treated with MPP
+ [41]
and antioxidant enzymes to prevent MPP
+-induced toxicity [41–
44].
Although its antioxidant properties have been extensively
described, a question remains to be answered: How does exogenous
urate prevents oxidant toxicity? Ascorbate, an important antiox-
idant in the CNS [45–47], is present at high levels in neurons
where its concentration is thought to be raised and maintained by
the sodium-dependent vitamin C transporter-2 (SVCT2) [48,49].
Urate may protect through a similar mechanism that relies on the
elevation of intracellular antioxidant content as was demonstrated
here with exogenous urate substantially increasing intracellular urate
in cortical neuronal cultures. By contrast, although Guerreiro et al.
[25] reported a similar protective effect of urate on dopaminergic
neurons in primary cultures, they did not find an associated
increase in intracellular urate, possibly due to a greater sensitivity
of our electrochemistry-based analytical methods or other
differences between our studies.
To directly address the hypothesis that endogenous urate
contributes to dopaminergic neuron resistance to toxicants, MPP
+
toxicity was assessed in cultures expressing the UOx enzyme,
which catalyzes urate degradation to allantoin. UOx is not
normally synthesized in the mouse brain where, like in humans,
urate is the enzymatic end product of the purine catabolism.
Transgenic UOx expression reduced basal levels of urate both in
cortical neurons and cortical astrocytes, even if this effect was not
proportional to the increasing levels of UOx protein expression
and enzyme activity observed with increasing transgene copy
number. In neuron-enriched cultures, dopaminergic neurons
expressing UOx were slightly more vulnerable to MPP
+ compared
to wild-type neurons. In neuron-astrocyte cultures, transgenic UOx
markedly exacerbated the toxicity and increased the potency of
MPP
+ even though we did not see a greater decrease in
intracellular urate concentration in astrocytes than in neurons.
Because we were not able to measure urate content in ventral
mesencephalic astrocytes and dopaminergic neurons due to their
low number, we employed their cortical counterparts. Although
urate transporter properties for each cell type are not expected to
differ across brain regions, we cannot be sure that the changes in
intracellular urate demonstrated in cortical cultures after both
pharmacologic and genetic manipulations were achieved in
ventral mesencephalic cells as well. Moreover, we cannot exclude
that culturing neurons with astrocytes might affect the intracellular
urate content in neurons. Nevertheless, our consistent observation
of potentiated protection by astrocytes in cultures of dopaminergic
Figure 8. MPP
+ effect on non-Tg, Tg and Tg/Tg neuron-enriched cultures. A) MPP
+ effect on TH-IR cell number in non-Tg (n=18), Tg (n=35)
and Tg/Tg (n=8) neuronal cultures. B) MPP
+ effect on MAP-2-IR cell number in non-Tg (n=18), Tg (n=35) and Tg/Tg (n=8) cultures. C) Two-way
ANOVA followed by Bonferroni multiple comparison test: **P,0.01, ***P,0.001 vs respective non-Tg value;
###P,0.01 vs respective Tg value.
doi:10.1371/journal.pone.0037331.g008
Figure 9. MPP
+ effect on non-Tg, Tg and Tg/Tg mixed neuron-astrocyte cultures. A) MPP
+ effect on TH-IR cell number in non-Tg (n=18), Tg
(n=34) and Tg/Tg (n=22) neuronal cultures. B) MPP
+ effect on MAP-2-IR cell number in non-Tg (n=18), Tg (n=34) and Tg/Tg (n=22). Two-way
ANOVA followed by Bonferroni multiple comparison test: *P,0.05, **P,0.01, ***P,0.001 vs respective non-Tg value.
doi:10.1371/journal.pone.0037331.g009
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on the neuroprotective effect of urate [35].
The small protective effect of urate in neuron-enriched cultures
containing few astrocytes and the far greater protection in neuron-
astrocyte cultures may reflect the same astrocyte-dependent
mechanism in both culture types. This interpretation is supported
by the absolute astrocyte dependence previously observed for
urate’s protective effect in spinal cord cultures [35]. Although the
content of astrocytes and other dividing glial cell populations was
pharmacologically reduced in our preparation of neuron-enriched
cultures, astroglia was not completely eliminated from these
cultures. Indeed a small astrocyte-independent effect of urate
acting directly on dopaminergic neurons cannot be excluded with
the available data.
How physiological levels of urate in astrocytes might play an
important role in dopaminergic neuron protection is not known. It
has been suggested that urate may confer neuroprotection via
astrocytes by stimulating their extracellular glutamate buffering
capacity or their release of neurotrophic factors [35,50]. An
intracellular antioxidant effect of urate on astrocytes might activate
such glial functions. Indeed astrocytes were found to be susceptible
to MPTP/MPP
+ treatment showing increased ROS level [51,52]
and reduced glutamate buffering capacity [53,54]. Therefore, even
though the toxicant concentration we employed was selected to be
subthreshold for altering astroglial viability, reducing basal levels
of urate in astrocytes might deplete their antioxidant reserves and
indirectly enhance toxic MPP
+ effects on neurons. Although urate
was found to protect neurons in association with the up-regulation
of EAAT1 glutamate transporter expression in astrocytes [35],
glutamate release was not detected in the striatum of MPP
+-
perfused mice [55] and NMDA antagonism did not prevent
MPP
+-induced dopaminergic cell death [56]. Further experiments
will be needed to clarify the mechanism by which astrocytes play a
facilitative role in the neuroprotective effect of urate and to
confirm urate’s protective effect in animal models of PD.
In conclusion, our data showed that intracellular urate may
modulate dopaminergic neuron resistance to environmental
toxins. This effect may be mediated by changes in astroglial urate
content. A greater understanding of how urate protects neurons in
models of PD may not only help elucidate its pathophysiology, it
may also help accelerate or refine current urate-targeting strategies
under investigation for their potential to slow or prevent PD
(http://clinicaltrials.gov/ct2/show/NCT00833690).
Materials and Methods
Mice
UOx Tg mice [37] were obtained from Kenneth L. Rock at
University of Massachusetts. Mice were backcrossed eight times on
the C57BL/6 genetic background and phenotyped by measuring
UOx activity in serum samples. Briefly, about two hundred mlo f
submandibular blood were collected from 1 month-old mice. Four
ml of serum sample were added to 96 ml of 130 mM urate in 0.1 M
borate (pH 8.5) and absorbance was read at 292 nm at the
beginning of the assay and after 4–6 hours incubation at 37uC.
Ethics Statement
All experiments were performed in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals, with approval from the animal subjects
review board of Massachusetts General Hospital (Permit Number:
2006N000120).
Neuron-enriched cultures
Ventral mesencephalon was dissected from embryonic day
E15–17 mouse embryos. Tissue was carefully stripped of their
meninges and digested with 0.6% trypsin for 15 min at 37uC.
Trypsinization was stopped by adding an equal volume of culture
preparation medium (DMEM/12, N2 supplement 5%, fetal
bovine serum (FBS) 10%, penicillin 100 U/ml and streptomycin
100 mg/ml) to which 0.02% deoxyribonuclease I was added. The
solution was homogenized by pipetting up and down, pelleted and
re-suspended in culture medium (Neurobasal medium (NBM), B27
supplement 2%, L-gluatamine (2 mM), penicillin 100 U/ml and
streptomycin 100 mg/ml). The solution was brought to a single cell
suspension by passage through a 40-mm pore mesh. Cells were
seeded at a density of 220,000 cells/cm
2 onto 96 well plates or
chamber-slides coated with poly-L-lysine (100 mg/ml)/DMEM/
F12) and cultured at 37uC in humidified 5% CO2-95% air. On
the third day half medium was replaced with fresh NBM
containing the antimetabolite cytosine arabinoside (Ara-
C,10 mM) to inhibit glial growth and glucose 6 mM. Medium
was fully changed after 24 hours and then a half volume was
replaced every other day. After 6 days in vitro (DIV) cultures were
pretreated with urate or vehicle, and 24 hours later MPP
+ or
vehicle was added. Cultures were constitute of .95% neurons, of
which 2–3% were dopaminergic neurons and ,5% astrocytes;
microglia and oligodendrocytes were not detected (See Figure 1).
For Tg neuronal cultures, individual cultures were prepared
from the ventral mesencephalon of individual embryos generated
by crossing two Tg mice (with a resulting distribution of 23% non-
Tg, 44% Tg and 33% Tg/Tg). The rest of the brain was used for
phenotyping by western blotting. Brain tissue extracts negative for
UOx staining were considered non-Tg; tissue, positive for UOx
staining were considered Tg when UOx/actin value was .0.1 and
#0.6, and Tg/Tg when UOx/actin value was .1.5. Cultured cell
phenotypes were confirmed by measuring UOx activity in the cell
medium.
Neuron-astrocyte cultures
Tissue was processed as described above but no Ara-C was
added to the cultures. At 4 DIV cells were treated with urate or
vehicle, 24 hour later MPP
+ or vehicle was added. Cultures
comprised 45–60% neurons, of which 2–3% were dopaminergic
neurons, 40–50% astrocytes and ,1 microglia, oligodendrocytes
were not detected.
Immunocytochemistry: After treatments cultures were fixed
with 4% paraformaldehyde for 1 hour at room temperature.
Then, cells were loaded with a blocking solution (0.5% albumin,
0.3% Triton-X 100 in phosphate buffer saline) for 30 min at room
temperature and then incubated with a mouse anti-TH (1:200,
Millipore, Temecule, CA) and a rabbit anti-MAP-2 antibody
(1:200, Millipore, Temecule, CA), or a rabbit anti-GFAP
antibody, overnight at 4uC to label dopaminergic neurons neurons
and astrocytes, respectively. Cultures were loaded with a cy3-
conjugated anti-mouse antibody (1:500, Jackson InnunoResearch
Laboratories, Inc.; West Grove, PA) and a FITC-conjugated anti-
rabbit antibody (1:300, Jackson InnunoResearch Laboratories,
Inc.; West Grove, PA) 2 hours at room temperature. Cultures
were imaged using an Olympus BX50 microscope with a 206/
0.50 objective and Olympus DP70 camera. Images were processed
with DP Controller software (Olympus) and merged with ImageJ
(NIH). Cells cultured in plates were observed with a Bio-Rad
Radiance 2100 confocal laser-scanning microscope with krypton-
argon and blue diode lasers. Images were acquired through a Plan
Fluor DIC ELWD 206/0.45 Ph1 DM ‘/0–2 WD 7.4 objective
on an inverted Nikon Eclipse TE300 fluorescent microscope with
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emission (green) and 590/617 nm excitation-emission (red).
Neurite length was measured by the Simple Neurite Tracer tool
of ImageJ software. In each sample, neurite length was determined
by the average of the longest neurite of 100 TH-IR neurons
randomly selected in the well. Neurons having neurites ending
outside the optic field were excluded from the analysis. Values
were expressed in mm.
High-Performance Liquid Chromatography
Cells were scraped in a solution of 150 mM phosphoric acid,
0.2 mM EDTA, and 1 mM 3,4-dihydroxybenzylamine (DHBA;
used as internal standard), clarified by centrifugation and filtered
through a 0.2 mm Nylon microcentrifuge filter (Spin-X, Corning).
Samples were chromatographed by a multi-channel electrochem-
ical/UV HPLC system with effluent from the above column
passing through a UV-VIS detector (ESA model 528) set at
254 nm and then over a series of electrodes set at 2100 mV,
+250 mV and +450 mV. Urate was measured on the +250 mV
electrode with a limit of detection at 0.0001 mg/dl. In order to
generate a gradient, two mobile phases were used. Mobile phase B
increased linearly from 0% to 70% between 6
th and 14
th min of
the run and immediately reduced to 0% at 17.4 min and allowed
to re-equilibrate for the final 3.6 min. Mobile phase A consisted of
0.2 M potassium phosphate and 0.5 mM sodium 1-pentanesulfo-
nate; mobile phase B consisted of the same plus 10% (vol/vol)
acetonitrile. Both mobile phases were brought to pH 3.5 with 85%
(wt/vol) phosphoric acid.
Western blot assay
Cells were scraped in RIPA buffer (Sigma Co., St. Luis, MO)
and loaded (50 mg of proteins per well) into a 10% SDS-PAGE gel.
Proteins were then transferred electrophoretically onto 0.2 m
nitrocellulose membranes (Biorad Laboratories) and probed with
a rabbit polyclonal antibody anti-UOx (1:200; Santa Cruz, CA)
overnight at 4uC. After washing in Tris Buffer Saline containing
0.1% Tween20, membranes were incubated with a horseradish
peroxidase-conjugated anti-rabbit IgG (1:2000; Pierce, Biotech-
nology, Rockford, IL, USA) for 2 hours at room temperature.
Proteins were visualized using chemiluminescence (Immobilon,
Millipore). In order to normalize the values of UOx staining, b-
actin was detected in the same western blot run. Membranes were
incubated for 2 hours at room temperature with an anti-b-actin
antibody (1:2000; Sigma, St Louis, MO) and then with a
horseradish peroxidase-conjugated anti-rabbit IgG (1:5000;
Pierce, Biotechnology, Rockford, IL) for 2 hours. Membranes
were developed as above. Bands were acquired as JPG files and
densitometric analysis of bands was performed by ImageJ
software. UOx/b-actin values were expressed as arbitrary units.
UOx activity assay
Cell medium was added to 0.5 mg/ml urate and absorbance
was red at 292 nm before and after 24 hours incubation at 37uC.
Activity was calculated as percentage of absorbance decrease in
comparison to starting values.
Protein detection: Proteins were quantified in 4 ml of each
sample using Bio-Rad Protein Assay reagent (Bio-Rad, Hercules,
CA, USA) and measured spectrophotometrically at 600 nm with
Labsystems iEMS Analyzer microplate reader.
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